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Previewsout the bulk of ubiquitin recognition func-
tions when proteasomes are not over-
loaded. These data suggest that an
Rpn13 inhibitor should have a wider ther-
apeutic window than inhibitors of proteo-
lytic sites (Figure 1B). Taken together, this
study by Anchoori et al. (2013) validates
the proteasome ubiquitin receptor
Rpn13 as a druggable target and opens
a new road to extend the therapeutic
application of proteasome inhibitors to
the treatment of solid tumors.
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Lung cancers are divided into four types according to their histologic appearance. Therapeutic decisions are
partly based on histology. A recent study indicates that certain molecular alterations associate with histology
and that therapies directed to these molecular changes improve outcome, indicating that genomic informa-
tion should be incorporated into future tumor classification.Lung cancers are the most common
cause of cancer death worldwide. For
many years, lung cancer histologies
have been determined according to the
World Health Organization (WHO) clas-
sification based primarily on the light
microscopic appearance of the malignant
cells (adenocarcinoma, squamous carci-
noma, large cell carcinomas, and small
cell carcinoma). The most recent pro-
posed WHO modifications reclassified
some adenocarcinomas into adeno-
carcinoma in situ, incorporating some
prior bronchioalveolar carcinomas and
minimally invasive or invasive carcinomas
with specification of the predominant
histologic pattern (Travis et al., 2011). In
past years, small cell carcinomas mixedwith large cell carcinoma (the so-called
22/40 subtype) were distinct within the
small cell classification, but later revision
classified these as either small cell car-
cinoma or large cell undifferentiated
carcinomas with neuroendocrine features
(Travis et al., 2004). Mixed small cell/
adenocarcinoma remained as a histologic
designation. Tumors where no differ-
entiation could be determined by histo-
logic appearances or immunohisto-
chemical staining for adenocarcinoma
or squamous cell carcinoma features
were designated as large cell undifferenti-
ated carcinomas. The WHO classification
is scheduled for revision in 2014.
Enter genomic testing. The paper
from the Clinical Lung Cancer GenomeProject (CLCGP) and Network Genomic
Medicine (NGM) team sheds consider-
able light on the relationship between
histologic appearance and genomic
abnormalities [The Clinical Lung Genome
Project (CLCGP) and Network Genomic
Medicine (NGM), 2013]. The authors
report that almost all cases of large cell
undifferentiated carcinomas could be
reclassified and assigned to one of the
other histologic types based on both
immunohistochemistry and genomic
alterations. These findings have con-
siderable relevance to patients with a his-
tologic diagnosis of large cell carcinoma.
Clinically, these patients are currently
grouped with patients with adenocarci-
nomas and treated with cytotoxicDecember 9, 2013 ª2013 Elsevier Inc. 693
Cancer Cell
Previewschemotherapy (Scagliotti et al., 2008).
Going forward, patients with large cell
carcinoma that have genetic features
associated with squamous cancers
should be considered for clinical trials
with tailored therapies for squamous
cancer (e.g., FGFR amplification or
SOX2 or DDR2 mutation) or cytotoxic
chemotherapy for squamous cancer
(i.e., patients with squamous cancers
should not receive pemetrexed or beva-
cizumab) (Scagliotti et al., 2008; Johnson
et al., 2004). In contrast, large cell carci-
nomas assigned to the group with
adenocarcinoma-type genetic features
should receive a specific adenocarci-
noma driver therapy (e.g., EGFR or
ALK tyrosine kinase inhibitors) if a
driver is present or a cytotoxic chemo-
therapy for adenocarcinoma (e.g., peme-
trexed) if no drivers are identified. Large
cell carcinomas with neuroendocrine
features should be treated as small cell
carcinomas.
Many questions remain, even with
this extensive genetic analysis. Should
all lung cancer patients undergo exten-
sive genetic testing and/or next-genera-
tion sequencing? Although this paper
shows that this approach is increasingly
feasible and the advantages of providing
diagnostic, prognostic and treatment
related information in one package be-
comes increasingly attractive, the answer
is probably not yet. Current guidelines
suggest testing all adenocarcinomas or
tumors with adenocarcinoma com-694 Cancer Cell 24, December 9, 2013 ª201ponents for EGFR or ALK alterations
(Lindeman et al., 2013). This study from
the CLCGP and NGM would indicate
that this guideline would be relevant for
large cell carcinomas as well, because
many would have genetic features similar
to adenocarcinoma. The guideline was
developed in large part because EGFR
and ALK TKIs were shown to be superior
to chemotherapy in patients with lung
adenocarcinoma with EGFR or ALK
alterations, respectively (Lindeman et al.,
2013). Guideline recommendations for
testing the other genetic alterations found
in adenocarcinomas will await clinical
trials establishing efficacy of oncogene-
targeted therapies in these subgroups.
Similarly, routine testing for the genetic
alterations typically found in squamous
carcinomas or neuroendocrine carci-
nomas (small cell or large cell) must await
clinical trials showing the efficacy of
targeted therapy. These data should be
considered in the revised WHO classi-
fication, especially as they relate to large
cell carcinomas.
Of course, the primary reason for clas-
sification of tumors is to better assign
appropriate therapy for our patients. In
the end, the histologic subtype may be
of little importance if an oncogene is
identified in a tumor sample and the
tumor can be treated effectively with a
targeted therapy. Indeed, this type of
genomic reclassification may one day
extend beyond the current boundaries
of organ-specific tumor classification.3 Elsevier Inc.The term ‘‘ALKoma’’ was recently pro-
posed, and early data suggest that multi-
ple different tumor types harboring ALK
gene fusions can respond to an ALK TKI
(Mano, 2012).
These data strongly suggest that
clinical treatment decisions must take
staging classification, histology, and ge-
netic features into consideration before
assigning therapy. They also highlight
the necessity of more widespread genetic
analyses in the clinical trials of all lung
cancer histologies.REFERENCES
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